ImmunXperts
ActiveSummary
ImmunXperts has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show negative equity (-€1.6m) and a net result of -€3.0m. Equity remains stable across the filed fiscal years (±1.3% per year). Its solvency ranks better than 9% of 247 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.5% (low).
Checked score
Score 2024
Axes · tick = 2023
Profitability0▼-46
Solvency8▼-30
Growth32▼-20
Track record100
Bankruptcy probability, 12 months
0.5%
Low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.46 against 0.6 in 2023; short-term debt: 114.9% and cash: 15.8% of total assets), and equity is negative.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
-16.7%
Return on assets
-31.1%
Age of the figures
21 mo
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Negative equity
The 2024 annual accounts show negative equity and a net loss.
NBB · annual accounts 2024Equity per financial year
18192021222324
2018 to 2024 · latest year -€1.6m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 08-07-2025, 23 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
23 d early
2023
33 d early
2022
16 d late
2021
39 d early
2020
30 d late
2019
9 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 10 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (1)
History
ImmunXperts was incorporated on 16 May 2014 by B.L.A. Consult and two natural persons, with a starting capital of EUR 61,500.12 Between 2014 and 2020 the capital was increased 3 times, most recently to EUR 830,879.345 The registered office was moved to Gosselies in 2024.6 The board currently has 5 members; Ganbaru Consult SRL has served longest, since 2020.7 Total assets rose from EUR 2.7 million in 2018 to EUR 9.6 million in 2024 and headcount from 7.4 to 26.7 full-time equivalents.8
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Public money
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€3.0m▼ 1,018%
2023 · -€266,255
Working capital
-€6.0m▼ 58.7%
2023 · -€3.8m
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Operating result-€177,814▼ 33.4%-€34,066▲ 80.8%€336,947-€306,651-€2.7m▼ 769%
Net result-€3,864within the sector's middle half€238,014within the sector's middle half€458,486above the sector's middle half▲ 92.6%-€266,255within the sector's middle half-€3.0mbelow the sector's middle half▼ 1,018%
Equity€1.5mwithin the sector's middle half▲ 9.0%€1.5mwithin the sector's middle half▲ 0.3%€1.8mwithin the sector's middle half▲ 21.5%€1.4mwithin the sector's middle half▼ 20.5%-€1.6mbelow the sector's middle half
Total assets€3.0mwithin the sector's middle half▲ 14.4%€5.3mwithin the sector's middle half▲ 73.3%€6.7mwithin the sector's middle half▲ 26.0%€10.8mabove the sector's middle half▲ 62.8%€9.6mwithin the sector's middle half▼ 11.7%
Debt€1.6m▲ 19.9%€3.8m▲ 140%€4.9m▲ 27.8%€9.4m▲ 92.9%€11.2m▲ 18.5%
Working capital€569,388within the sector's middle half▲ 23.5%-€429,845below the sector's middle half€1.3mwithin the sector's middle half-€3.8mbelow the sector's middle half-€6.0mbelow the sector's middle half▼ 58.7%
Solvency47.6%within the sector's middle half▼ 2.4pp27.5%within the sector's middle half▼ 20.0pp26.5%within the sector's middle half▼ 1.0pp12.9%below the sector's middle half▼ 13.6pp-16.7%below the sector's middle half▼ 29.7pp
Current ratio1.54within the sector's middle half▼ 0.060.88below the sector's middle half▼ 0.661.35within the sector's middle half▲ 0.470.60below the sector's middle half▼ 0.750.46below the sector's middle half▼ 0.14
Return on assets (ROA)-0.1%within the sector's middle half▼ 0.5pp4.5%within the sector's middle half▲ 4.6pp6.9%above the sector's middle half▲ 2.4pp-2.5%within the sector's middle half▼ 9.3pp-31.1%below the sector's middle half▼ 28.6pp
Staff (FTE)13.2within the sector's middle half▲ 32.0%18.3within the sector's middle half▲ 38.6%22within the sector's middle half▲ 20.2%24.6within the sector's middle half▲ 11.8%26.7above the sector's middle half▲ 8.5%
above
within
below
the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €2.7m in 2024 against €306,651 in 2023; the loss grows and 2024 has the lowest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €9.6m
Fixed assets
€4.6m ▼ 12.4%
Current assets
€5.0m ▼ 10.9%
Key figures and ratios
EBITDA
-€1.8m▼
2023 · €253,806
Cash flow
-€2.1m▼
2023 · €294,203
Quick ratio
0.30▼
2023 · 0.42
Debt to equity
-6.98▼
2023 · 6.72
Interest coverage
-5.22▼
2023 · 3.66
Debt ≤ 1 year
€11.0m▲
2023 · €9.4m
Debt > 1 year
€1,522▼
2023 · €32,385
Income taxes
€2,673▲
2023 · €927
Staff costs
€2.2m▼
2023 · €2.3m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 598 companies that looked in July 2024 the way this one looks now, 9.4% went bankrupt within 24 months and 83% are still going.
- Small
- 10 to 20 years old
- negative equity
- a loss of 10% of the balance sheet or more
9.4%
went bankrupt
6.0%
stopped otherwise
83%
still going
A further 1.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.5% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,340 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 598 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | €2,874 | €11,940 | €0 | ▼ 100% |
| Remuneration, social security and pensions62 | - | €1.8m | €1.7m | €2.3m | €2.2m | ▼ 5.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €591,269 | €692,216 | €678,011 | €560,457 | €888,077 | ▲ 58.5% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €15,765 | -€15,765 | ▼ 200% |
| Other operating charges640/8 | - | €5,639 | €5,422 | €1,252 | €18,234 | ▲ 1,356% |
| Non-recurring operating charges66A | - | - | €828 | €0 | - | - |
| Gross operating margin9900 | €1.5m | €2.4m | €2.7m | €2.6m | €393,338 | ▼ 84.7% |
| Operating profit (loss)9901 | -€177,814 | -€34,066 | €336,947 | -€306,651 | -€2.7m | ▼ 769% |
| Financial income75/76B | - | €299,249 | €146,339 | €110,640 | €30,066 | ▼ 72.8% |
| Recurring financial income75 | €187,918 | €296,081 | €146,339 | €110,640 | €30,066 | ▼ 72.8% |
| Non-recurring financial income76B | - | €3,167 | €0 | - | - | - |
| Financial charges65/66B | - | €26,210 | €23,946 | €69,316 | €339,893 | ▲ 390% |
| Recurring financial charges65 | €13,082 | €26,210 | €23,946 | €69,316 | €339,893 | ▲ 390% |
| Profit (loss) for the period before taxes9903 | -€2,978 | €238,972 | €459,341 | -€265,328 | -€3.0m | ▼ 1,021% |
| Income taxes67/77 | €886 | €958 | €855 | €927 | €2,673 | ▲ 188% |
| Profit (loss) for the period9904 | -€3,864 | €238,014 | €458,486 | -€266,255 | -€3.0m | ▼ 1,018% |
| Profit (loss) for the period to be appropriated9905 | -€3,864 | €238,014 | €458,486 | -€266,255 | -€3.0m | ▼ 1,018% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €3.0m | €5.3m | €6.7m | €10.8m | €9.6m | ▼ 11.7% |
| Fixed assets21/28 | €1.4m | €2.1m | €1.7m | €5.2m | €4.6m | ▼ 12.4% |
| Intangible fixed assets21 | €941,451 | €622,527 | €326,311 | €128,551 | €101,930 | ▼ 20.7% |
| Tangible fixed assets22/27 | €459,322 | €1.5m | €1.3m | €5.0m | €4.4m | ▼ 12.3% |
| Plant, machinery and equipment23 | - | €1.3m | €995,672 | €1.3m | €1.1m | ▼ 14.9% |
| Furniture and vehicles24 | - | €71,928 | €22,851 | €201,813 | €134,538 | ▼ 33.3% |
| Leasing and similar rights25 | - | €121,774 | €91,331 | €60,887 | €29,548 | ▼ 51.5% |
| Other tangible fixed assets26 | - | - | - | - | €3.1m | - |
| Assets under construction and advance payments27 | - | - | €179,139 | €3.4m | €0 | ▼ 100% |
| Financial fixed assets28 | €28,000 | €37,730 | €37,730 | €97,940 | €88,210 | ▼ 9.9% |
| Current assets29/58 | €1.6m | €3.2m | €5.0m | €5.6m | €5.0m | ▼ 10.9% |
| Stocks and contracts in progress3 | - | €671,076 | €1.3m | €1.6m | €1.7m | ▲ 6.5% |
| Stocks30/36 | - | €671,076 | €1.3m | €1.6m | €1.7m | ▲ 6.5% |
| Amounts receivable within one year40/41 | €844,504 | €1.7m | €1.2m | €1.7m | €1.5m | ▼ 11.9% |
| Trade receivables40 | - | €1.3m | €815,432 | €735,289 | €1.2m | ▲ 58.1% |
| Other amounts receivable41 | - | €331,972 | €418,520 | €928,988 | €304,451 | ▼ 67.2% |
| Cash at bank and in hand54/58 | €309,151 | €563,572 | €605,203 | €1.8m | €1.5m | ▼ 15.3% |
| Deferred charges and accrued income490/1 | - | €236,866 | €1.9m | €537,123 | €285,062 | ▼ 46.9% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €3.0m | €5.3m | €6.7m | €10.8m | €9.6m | ▼ 11.7% |
| Equity10/15 | €1.5m | €1.5m | €1.8m | €1.4m | -€1.6m | ▼ 214% |
| Contributions10/11 | €830,879 | €830,879 | €830,879 | €830,879 | €830,879 | = |
| Capital10 | - | €830,879 | €830,879 | €830,879 | €830,879 | = |
| Issued capital100 | - | €830,879 | €830,879 | €830,879 | €830,879 | = |
| Reserves13 | €3,683 | €15,584 | €38,508 | €38,508 | €38,508 | = |
| Non-distributable reserves130/1 | - | €15,584 | €38,508 | €38,508 | €38,508 | = |
| Legal reserve130 | - | €15,584 | €38,508 | €38,508 | €38,508 | = |
| Profit (loss) carried forward14 | €66,115 | €292,228 | €727,789 | €461,534 | -€2.5m | ▼ 645% |
| Investment grants15 | - | €315,712 | €169,373 | €73,044 | €42,978 | ▼ 41.2% |
| Amounts payable17/49 | €1.6m | €3.8m | €4.9m | €9.4m | €11.2m | ▲ 18.5% |
| Amounts payable after more than one year17 | €208,433 | €178,281 | €80,279 | €32,385 | €1,522 | ▼ 95.3% |
| Financial debts170/4 | - | €178,281 | €80,279 | €32,385 | €1,522 | ▼ 95.3% |
| Amounts payable within one year42/48 | €1.1m | €3.6m | €3.7m | €9.4m | €11.0m | ▲ 17.0% |
| Current portion of amounts payable after more than one year42 | - | €152,949 | €84,644 | €41,152 | €30,862 | ▼ 25.0% |
| Financial debts43 | - | - | - | - | €1.1m | - |
| Credit institutions430/8 | - | - | - | - | €1.1m | - |
| Trade debts44 | €210,256 | €932,338 | €118,841 | €1.3m | €477,953 | ▼ 64.6% |
| Suppliers440/4 | - | €932,338 | €118,841 | €1.3m | €477,953 | ▼ 64.6% |
| Taxes, remuneration and social security45 | - | €326,717 | €293,924 | €562,318 | €628,084 | ▲ 11.7% |
| Taxes450/3 | - | €0 | - | - | - | - |
| Remuneration and social security454/9 | - | €326,717 | €293,924 | €562,318 | €628,084 | ▲ 11.7% |
| Other amounts payable47/48 | - | €2.2m | €3.2m | €7.5m | €8.8m | ▲ 17.5% |
| Accrued charges and deferred income492/3 | - | €68,030 | €1.1m | €0 | €173,899 | - |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€3,864 | €238,014 | €458,486 | -€266,255 | -€3.0m | ▼ 1,018% |
| + Depreciation and write-downs630 | €591,269 | €692,216 | €678,011 | €560,457 | €888,077 | ▲ 58.5% |
| Operating cash flow (approximation) | €587,405 | €930,230 | €1.1m | €294,203 | -€2.1m | ▼ 810% |
| Investment in fixed assets (approximation) | - | -€1.4m | -€200,486 | -€4.1m | -€240,434 | ▲ 94.2% |
| Change in cash | - | €254,421 | €41,631 | €1.2m | -€272,973 | ▼ 123% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2026
08-01
State Gazette act
Appointment: Forvis Mazars Bedrijfsrevisoren - Forvis Mazars Réviseurs D'Entreprises (statutory auditor)2 facts ▸
State Gazette act
Appointment: Forvis Mazars Bedrijfsrevisoren - Forvis Mazars Réviseurs D'Entreprises (statutory auditor)
2 facts ▸
- Written decision, 16-10-2025
- Auditor appointment, Forvis Mazars Bedrijfsrevisoren - Forvis Mazars Réviseurs D'Entreprises (statutory auditor)
2025
08-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Weakest financial yearnet -€3.0m
Net result drops to -€3.0m, the lowest in the series.
28-06
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
02-02
State Gazette act
Registered officeRegistered-office move2 facts ▸
State Gazette act
Registered office
Registered-office move2 facts ▸
- Board meeting, 11-01-2024
- Registered-office move, Rue Clément Ader 10, 6041 Gosselies (Charleroi), Belgique
2023
16-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 16 days late
04-05
State Gazette act
Resignations & appointmentsPower of attorney · Mandate term7 facts ▸
State Gazette act
Resignations & appointments
Power of attorney · Mandate term7 facts ▸
- Board meeting, 15-03-2023
- Power of attorney, Kurt M Peeters
- Mandate term, jusqu'à la première des dates suivantes: (a) la date à laquelle le délégué cessera d'être employé au sein du groupe IQVIA (i.e., par la Société ou une de ses so…
- Mandate term, jusqu'à la première occurrence de (a) cinq (5) ans après la date de ces pouvoirs spéciaux ou (b) la révocation de ces pouvoirs spéciaux par le Conseil
- Mandate term, jusqu'à la première occurrence de (a) cinq (5) ans après la date de ces pouvoirs spéciaux ou (b) la révocation de ces pouvoirs spéciaux par le Conseil
- Mandate term, jusqu'à la première occurrence de (a) cinq (5) ans après la date de ces pouvoirs spéciaux ou (b) la révocation de ces pouvoirs spéciaux par le Conseil
- Mandate term, jusqu'à la première occurrence de (a) cinq (5) ans après la date de ces pouvoirs spéciaux ou (b) la révocation de ces pouvoirs spéciaux par le Conseil
14-02
State Gazette act
Resignation: Frank Swaelens (director)Appointment: Emmanuel Vanderhaegen (director) · Director discharge · Mandate compensation9 facts ▸
State Gazette act
Resignation: Frank Swaelens (director)
Appointment: Emmanuel Vanderhaegen (director) · Director discharge · Mandate compensation9 facts ▸
- General meeting, 01-02-2023
- Director resignation, Frank Swaelens (director)
- Director discharge, Frank Swaelens
- Director appointment, Emmanuel Vanderhaegen (director)
- Mandate compensation, Emmanuel Vanderhaegen
- Power of attorney, Jan-Frederik Keustermans
- Power of attorney, Kasper Theunissen
- Power of attorney, Michiel De Wolf
- Power of attorney, Talitha Crabbe
2022
31-12
Financial
Highest result since 2018net €458,486 ▲92.6%
Operating result €336,947, net result €458,486, both a record.
22-06
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
31-05
State Gazette act
Resignation: Nexelis Europe SRL (sole director)Appointments: Sofie Pattyn, Frank Swaelens and Clément Vanthournhout · Permanent representative: Benoit Bouche · Mandate compensation14 facts ▸
State Gazette act
Resignation: Nexelis Europe SRL (sole director)
Appointments: Sofie Pattyn, Frank Swaelens and Clément Vanthournhout · Permanent representative: Benoit Bouche · Mandate compensation14 facts ▸
- General meeting, 11-05-2022
- Director resignation, Nexelis Europe SRL (sole director)
- Director appointment, Sofie Pattyn (director)
- Mandate compensation, Sofie Pattyn
- Director appointment, Frank Swaelens (director)
- Mandate compensation, Frank Swaelens
- Director appointment, Clément Vanthournhout (director)
- Mandate compensation, Clément Vanthournhout
- Board meeting, 17-05-2022
- Power of attorney, Vahé Kalusyan
- Power of attorney, Ganbaru Consult SRL
- Director appointment, Sofie Pattyn (daily management delegate)
- +2 further facts in this act
2021
31-12
Financial
Back to profitnet €238,014
Net result €238,014 after one loss-making year.
Show earlier events
30-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 30 days late
14-04
State Gazette act
Appointments: Ganbaru Consult SRL (daily management delegate) and Vahé Kalusyan (daily management delegate)Permanent representative: Sofie Pattyn · Mandate compensation · Power of attorney9 facts ▸
State Gazette act
Appointments: Ganbaru Consult SRL (daily management delegate) and Vahé Kalusyan (daily management delegate)
Permanent representative: Sofie Pattyn · Mandate compensation · Power of attorney9 facts ▸
- Board meeting, 20-10-2020
- Director appointment, Ganbaru Consult SRL (daily management delegate)
- Permanent representative, Sofie Pattyn
- Mandate compensation, Ganbaru Consult SRL
- Director appointment, Vahé Kalusyan (daily management delegate)
- Power of attorney, Vahé Kalusyan
- Mandate term, durée indéterminée
- Mandate limit, contrats et transactions jusqu'à 80.000 EUR maximum (items c, d, f, i, j); prime d'assurance annuelle 100.000 EUR maximum (item k); litiges et règlements amiabl…
- Mandate termination, Elle prend fin automatiquement dès que le mandataire cesse d'être un employé de la Société ou d'une société liée à la Société au sens de l'article 1:20 du Code…
2020
22-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
16-04
State Gazette act
Resignations: INVEST 4 IMMUNX, CTJ and 4 othersAppointment: Sardi Hoidings (sole director) · Permanent representative: Benoit Bouche · Statutes amendment18 facts ▸
State Gazette act
Resignations: INVEST 4 IMMUNX, CTJ and 4 others
Appointment: Sardi Hoidings (sole director) · Permanent representative: Benoit Bouche · Statutes amendment18 facts ▸
- General meeting, 19-03-2020
- Statutes amendment
- Capital, €830.878,94
- Director resignation, INVEST 4 IMMUNX (director)
- Director resignation, CTJ (director)
- Director resignation, BAM CONSULT (director)
- Director resignation, GANBARU (director)
- Director resignation, SAMBRINVEST (director)
- Director resignation, SAMBRINVEST SPIN OFF/SPIN-OUT (director)
- Director discharge, INVEST 4 IMMUNX
- Director discharge, CTJ
- Director discharge, BAM CONSULT
- +6 further facts in this act
26-03
State Gazette act
Capital & sharesCapital increase · Bank account · Capital5 facts ▸
State Gazette act
Capital & shares
Capital increase · Bank account · Capital5 facts ▸
- Board meeting, 03-03-2020
- Capital increase, €86.150,84
- Bank account, BE35 3631 9891 7637
- Capital, €830.878,94
- Statutes amendment
2019
24-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
23-01
State Gazette act
Capital & sharesShare issue · Capital increase · Power of attorney4 facts ▸
State Gazette act
Capital & shares
Share issue · Capital increase · Power of attorney4 facts ▸
- General meeting, 27-12-2018
- Share issue, 105062, warrants
- Capital increase
- Power of attorney, deux administrateurs agissant conjointement
2018
24-12
State Gazette act
Capital & sharesStatutes amendment1 fact ▸
State Gazette act
Capital & shares
Statutes amendment1 fact ▸
- Statutes amendment
10-07
State Gazette act
Reappointment: BAM Consult BVBA (director)Permanent representative: Philippe Stas · Resignation: BLA Consult BVBA (director)4 facts ▸
State Gazette act
Reappointment: BAM Consult BVBA (director)
Permanent representative: Philippe Stas · Resignation: BLA Consult BVBA (director)4 facts ▸
- General meeting, 05-06-2018
- Director reappointment, BAM Consult BVBA (director)
- Permanent representative, Philippe Stas
- Director resignation, BLA Consult BVBA (director)
20-06
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
13-10
State Gazette act
Permanent representative: Philippe JanssensPublication correction3 facts ▸
State Gazette act
Permanent representative: Philippe Janssens
Publication correction3 facts ▸
- General meeting, 05-06-2017
- Permanent representative, Philippe Janssens
- Publication correction, 31-10-2016
30-06
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
24-01
State Gazette act
Resignations: Anne Prignon, Micheline Streel and 2 othersAppointments: SAMBRINVEST, SAMBRINVEST SPIN-OFF/SPIN-OUT and 2 others · Permanent representatives: Anne Prignon, Micheline Streel and 2 others13 facts ▸
State Gazette act
Resignations: Anne Prignon, Micheline Streel and 2 others
Appointments: SAMBRINVEST, SAMBRINVEST SPIN-OFF/SPIN-OUT and 2 others · Permanent representatives: Anne Prignon, Micheline Streel and 2 others13 facts ▸
- General meeting, 04-01-2017
- Director resignation, Anne Prignon (director)
- Director resignation, Micheline Streel (director)
- Director resignation, Sofie Pattijn (director)
- Director resignation, Philippe Stas (director)
- Director appointment, SAMBRINVEST (director)
- Permanent representative, Anne Prignon
- Director appointment, SAMBRINVEST SPIN-OFF/SPIN-OUT (director)
- Permanent representative, Micheline Streel
- Director appointment, B.L.A. CONSULT (director)
- Permanent representative, Philippe Stas
- Director appointment, GANBARU CONSULT (director)
- +1 further facts in this act
2016
14-11
State Gazette act
Resignations: Arno KROMMINGA, Sofie PATTYN and 3 othersAppointments: Sofie PATTYN, Anne Germaine Prignon and 5 others · Permanent representative: Thibault Benoit Jonckheere · Statutes amendment18 facts ▸
State Gazette act
Resignations: Arno KROMMINGA, Sofie PATTYN and 3 others
Appointments: Sofie PATTYN, Anne Germaine Prignon and 5 others · Permanent representative: Thibault Benoit Jonckheere · Statutes amendment18 facts ▸
- General meeting, 04-08-2016
- Statutes amendment
- Capital decrease, €665.500
- Capital increase, €744.728,1
- Capital, €744.728,1
- Director resignation, Arno KROMMINGA (director)
- Director resignation, Sofie PATTYN (director)
- Director resignation, B.L.A. Consult (director)
- Director resignation, SAMBRINVEST SPIN OFF / SPIN-OUT (director)
- Director resignation, INVEST4IMMUNX (director)
- Director appointment, Sofie PATTYN (director)
- Director appointment, Anne Germaine Prignon (director)
- +6 further facts in this act
24-08
State Gazette act
Appointment: CTJ Consulting (managing director)Permanent representative: Thibault Jonckheere · Suspensive condition4 facts ▸
State Gazette act
Appointment: CTJ Consulting (managing director)
Permanent representative: Thibault Jonckheere · Suspensive condition4 facts ▸
- Board meeting, 01-08-2016
- Director appointment, CTJ Consulting (managing director)
- Permanent representative, Thibault Jonckheere
- Suspensive condition, sous condition suspensive de sa nomination en tant qu'administrateur de la Société par l'assemblée générale
28-06
NBB filing
Annual accounts filed
fiscal year 2015 · full schema
2014
07-10
State Gazette act
Resignations: Sofie PATTYN, Armo KROMMINGA and B.L.A. CONSULT SPRLAppointments: Sofie PATTYN, Armo KROMMINGA and 3 others · Permanent representatives: Philippe STAS, Micheline STREEL and Philippus Maria Janssens de Varebeke · Capital increase22 facts ▸
State Gazette act
Resignations: Sofie PATTYN, Armo KROMMINGA and B.L.A. CONSULT SPRL
Appointments: Sofie PATTYN, Armo KROMMINGA and 3 others · Permanent representatives: Philippe STAS, Micheline STREEL and Philippus Maria Janssens de Varebeke · Capital increase22 facts ▸
- General meeting, 06-08-2014
- Capital increase, €151.000
- Capital increase, €453.000
- Capital, €665.500
- Statutes amendment
- Statutes amendment
- Director resignation, Sofie PATTYN (director)
- Director resignation, Armo KROMMINGA (director)
- Director resignation, B.L.A. CONSULT SPRL (director)
- Director appointment, Sofie PATTYN (director)
- Director appointment, Armo KROMMINGA (director)
- Director appointment, B.L.A. CONSULT SPRL (director)
- +10 further facts in this act
20-05
State Gazette act
IncorporationAppointments: Sofie PATTYN, Arno Jens KROMMINGA and B.L.A. Consult · Permanent representative: Philippe Paul STAS · Founding capital21 facts ▸
State Gazette act
Incorporation
Appointments: Sofie PATTYN, Arno Jens KROMMINGA and B.L.A. Consult · Permanent representative: Philippe Paul STAS · Founding capital21 facts ▸
- Incorporation, 15-05-2014
- Founding capital, €61.500
- Bank account, BNP PARIBAS FORTIS
- Founder, Sofie PATTYN
- Founder, Arno Jens KROMMINGA
- Founder, B.L.A. Consult
- Director appointment, Sofie PATTYN (director)
- Director appointment, Arno Jens KROMMINGA (director)
- Director appointment, B.L.A. Consult (director)
- Permanent representative, Philippe Paul STAS
- Mandate compensation, Sofie PATTYN
- Mandate compensation, Arno Jens KROMMINGA
- +9 further facts in this act
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
17 of 17 acts read
Directors · office · real estate
Directors
3 directors, 3 in day-to-day management, no change since 2023
Board 3
Clément Vanthournhout
CurrentDirector · since 11-05-2022
Sofie PATTYN
CurrentDirector · since 11-05-2022
Emmanuel Vanderhaegen
CurrentDirector · since 01-02-2023
12 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
BLACONSULT
Not recently confirmedDirector · since 15-05-2014 · Legal entity · perm. rep.: Philippe Paul STAS
Armo KROMMINGA
Not recently confirmedDirector · since 06-08-2014
B.L.A. CONSULT SPRL
Not recently confirmedDirector · since 06-08-2014 · Legal entity · perm. rep.: Philippe STAS
SAMBRINVEST SPIN OFF/SPIN-OUT SA
Not recently confirmedDirector · since 06-08-2014 · Legal entity · perm. rep.: Micheline STREEL
CTJ CONSULTING
Not recently confirmedDirector · since 04-08-2016 · Private limited company · perm. rep.: Thibault Jonckheere
Philippus JANSSENS de VAREBEKE
Not recently confirmedDirector · since 04-08-2016
Serge Louis Pampfer
Not recently confirmedObservateur du conseil d'administration · since 04-08-2016
Ganbaru Consult
Not recently confirmedDirector · since 04-01-2017 · Private limited company · perm. rep.: Sofie Pattijn
SAMBRINVEST SPIN-OFF/SPIN-OUT
Not recently confirmedDirector · since 04-01-2017 · Public limited company · perm. rep.: Micheline Streel
Société de Développement et de Participation du Bassin de Charleroi
Not recently confirmedDirector · since 04-01-2017 · Public limited company · perm. rep.: Anne Prignon
BAM CONSULT
Not recently confirmedDirector · since 05-06-2018 · Private limited company · perm. rep.: Philippe Stas
Sardi Hoidings
Not recently confirmedSole director · since 19-03-2020 · Legal entity · perm. rep.: Benoit Bouche
Day-to-day management 3
Ganbaru Consult SRL
CurrentDaily management delegate · since 19-03-2020 · Legal entity · perm. rep.: Sofie Pattyn
Vahé Kalusyan
CurrentDaily management delegate · since 20-10-2020
Sofie PATTYN
CurrentDaily management delegate · since 17-05-2022
1 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
CTJ CONSULTING
Not recently confirmedManaging director · since 01-08-2016 · Private limited company · perm. rep.: Thibault Jonckheere
Permanent representatives 1
Sofie Pattyn
CurrentPermanent representative · since 19-03-2020 · for Ganbaru Consult SRL
6 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Thibault Jonckheere
Not recently confirmedPermanent representative · since 04-08-2016 · for CTJ CONSULTING
Anne Prignon
Not recently confirmedPermanent representative · since 04-01-2017 · for Société de Développement et de Participation du Bassin de Charleroi
Micheline Streel
Not recently confirmedPermanent representative · since 04-01-2017 · for SAMBRINVEST SPIN-OFF/SPIN-OUT
Sofie Pattijn
Not recently confirmedPermanent representative · since 04-01-2017 · for Ganbaru Consult
Philippe Stas
Not recently confirmedPermanent representative · since 05-06-2018 · for BAM CONSULT
Benoit Bouche
Not recently confirmedPermanent representative · since 19-03-2020 · for Sardi Hoidings
Statutory auditor 1
Forvis Mazars Réviseurs d’Entreprises
CurrentStatutory auditor · since 30-12-2025
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Location & real-estate footprint
Registered office, Charleroi · 1 establishment unit since 2014
Ground area
1.1 ha
Building footprint
1,056 m²
Volume, LiDAR
15,201 m³
2 parcels, Wallonia · tallest building 17.3 m, ±5 floors. Linked by address, not a title deed.
1 establishment unit
IMXP
since 20142.231.201.819
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 52028B0295/02C000 | Wallonia | 7,830 m² | - | - |
| 52028B0295/00B002 | Wallonia | 3,131 m² | 1 · 1,056 m² | 17.2 m · 5 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
32 people since 2014, 18 in office
- Board
- Day-to-day management
- Statutory auditor
- not recently confirmed
- began earlier
| Name | Functions and periods |
|---|---|
| Sofie PATTYN |
|
| Clément Vanthournhout |
|
| Emmanuel Vanderhaegen |
|
| Ganbaru Consult SRL |
|
| Vahé Kalusyan |
|
| Forvis Mazars Réviseurs d’Entreprises |
|
| BLACONSULT |
|
| Armo KROMMINGA |
|
| B.L.A. CONSULT SPRL |
|
| SAMBRINVEST SPIN OFF/SPIN-OUT SA |
|
| CTJ CONSULTING |
|
| Philippus JANSSENS de VAREBEKE |
|
| Serge Louis Pampfer |
|
| Ganbaru Consult |
|
| SAMBRINVEST SPIN-OFF/SPIN-OUT |
|
| Société de Développement et de Participation du Bassin de Charleroi |
|
| BAM CONSULT |
|
| Sardi Hoidings |
|
| Frank Swaelens |
|
| Nexelis Europe SRL |
|
| BAM CONSULT |
|
| CTJ |
|
| GANBARU |
|
| INVEST4IMMUNX |
|
| Sambrinvest |
|
| SAMBRINVEST SPIN OFF/SPIN-OUT |
|
| BLA Consult BVBA |
|
| Anne PRIGNON |
|
| Micheline Streel |
|
| Philippe Stas |
|
| Arno Jens KROMMINGA |
|
| B.L.A. Consult |
|
Articles of association
Purpose
Le développement et la fourniture de services d'analyse ou de prédiction d'effets secondaires des produits pharmaceutiques... [full object text]
Structure & network
Owners and holdings
1 ownerChain of control
- Nexelis Europe
- ImmunXperts
Highest known parent: Nexelis Europe. The sources do not say who stands above it.
Owners 1
-
100%
Holdings 0
The accounts to 31-12-2024 list no holdings, and no other source names one.
According to the 2024 annual accounts of ImmunXperts and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
27 connected companiesThis company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
6K venture capital
Shared director
→
alarm industries association
Shared director
→
→
AZIMUT Entreprendre
Shared director
→
Show 23 more companies with a shared director
BePharBel Manufacturing
Shared director
→
BIO-SOURCING
Shared director
→
BRUSSELS SOUTH CHARLEROI AIRPORT
Shared director
→
Catalent Gosselies PS
Shared director
→
ENDO TOOLS THERAPEUTICS
Shared director
→
FONDS DE CAPITAL A RISQUE 2020
Shared director
→
HOLDING FINANCIERE DU PONANT
Shared director
→
IMBC 2020
Shared director
→
IMBC CAPITAL RISQUE
Shared director
→
OncoDNA
Shared director
→
SAMBRELEASE
Shared director
→
SOCIETE D'INVESTISSEMENT DE MONS, DU BORINAGE ET DU CENTRE
Shared director
→
SOCIETE D'INVESTISSEMENT ET DE FINANCEMENT DU BRABANT WALLON
Shared director
→
Société Nationale de Construction Aérospatiale
Shared director
→
Starter Fund
Shared director
→
Starter Wallonia Hainaut
Shared director
→
Bedal International
Shared corporate director
→
DIGITAL ATTRAXION
Shared corporate director
→
DREAMWALL
Shared corporate director
→
MoveUP
Shared corporate director
→
NOVAFORM PHARMA
Shared corporate director
→
RheaVita
Shared corporate director
→
THEODORUS IV
Shared corporate director
→
Capital and shareholders
Shareholders according to the acts
At incorporation
act of 20-05-2014 ↗
- Sofie PATTYN founder
- Arno Jens KROMMINGA founder
- B.L.A. Consult (BE 0892.222.331) founder
The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.
Capital over the years
- 16-04-2020 Capital stated in the act · 830,878.94 EUR · 1,272,414 shares
- 26-03-2020 Capital increase of 86,150.84 EUR · to 830,878.94 EUR · 105,062 new shares
- 14-11-2016 Capital reduction of 665,500 EUR · to 0 EUR · to absorb losses
- 14-11-2016 Capital increase of 744,728.10 EUR · to 744,728.10 EUR · 908,205 new shares
- 07-10-2014 Capital increase of 151,000 EUR · to 212,500 EUR · 184,146 new shares
- 07-10-2014 Capital increase of 453,000 EUR · to 665,500 EUR · from reserves
- 20-05-2014 Incorporation · 61,500 EUR · 75,000 shares
Public money · subsidies and aid
European research
1 project · 256,320 EUR EU contributionProgrammes
Projects
anti-Bacterial Innovative Vaccine Training Network.
Similar companies · same sector, comparable size
ConvEyXo
BE 0725.874.259
Charleroi · Eq €1,388,840
OLFADOG BIOTECH
BE 0794.892.333
Waterloo · Eq €1,442,474
DOCTEUR BOSQUART
BE 0885.419.760
Sint-Agatha-Berchem · Eq €1,449,034
E-Proteins
BE 0843.454.986
Gembloux · Eq €1,449,395
IPRATECH
BE 0893.778.586
Charleroi · Eq €1,455,788
Of 762 companies in sector 72101 we hold annual accounts for 484. 283 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded16-05-2014
Fiscal year end31-12
Abbreviation FR
IMXP
Activities, NACEBEL 2025
72101Research and development on biotechnology
E-invoicing
Reachable via Peppol
Peppol ID
0208:0552755587
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 30 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.